Browsing Tag
Structure Therapeutics
2 posts
Oral GLP-1 race heats up as Structure Therapeutics posts strong ACCESS data for aleniglipron
Find out how Structure Therapeutics’ oral GLP-1 drug aleniglipron delivered double-digit weight loss in the ACCESS trial and what it means for the obesity market.
Which biotech companies are developing next-gen GLP-1 alternatives—and can they compete with Novo Nordisk and Eli Lilly by 2030?
Discover how biotech players like Viking, Structure, and Altimmune are developing next-gen GLP-1 drugs to challenge obesity leaders Novo Nordisk and Eli Lilly. Read more.